Firstly, we would like to thank Finsterer and their partners for reading our article1 with so much interest and dedication. As well as the Medicina Intensiva Journal for their kindness allowing us to make the reply that we will develop next.

In June 2020, we published in the online version of this journal, an article2 showing the clinical case of a 55 year old patient with SARS-CoV-2 infection and neurological symptoms, in which after performing the relevant tests, a sensory-motor polyneuropathy was detected. Being this article, the first Guillain–Barré syndrome (GBS) case reported in Spain, in the course of an infection by the SARS-CoV-2 virus and in addition, supporting the hipótesis spread from China, in January 2020, GBS associated with SARS-CoV-2, chance or coincidence?3

Subsequently, such was our concern that we conducted a bibliographic search in the Medline database (PubMed) on published cases of GBS in the worldwide context of SARS-CoV-2 infection. Starting from December 2019 to June 30, 2020, with a total of 39 clinical cases reported. Immediately after the data collection and statistical analysis, we sent a letter to the editor of the Medicina Intensiva Journal; available online since September 2020 and titled: SARS-CoV-2, a new causative agent of Guillain–Barré syndrome?1 Finsterer et al., show their disagreement due to the lack of conviction in our publication about the association of GBS and SARS-CoV-2, and even allude to the fact that vaccination can also trigger GBS. From our utmost respect, we would like to emphasize the time difference, more than a year between both publications. Therefore, the experience and the increase in the number of subsequent cases have shown the strength of the SARS-CoV-2 and GBS association. On the whole, the authors, when writing these publications, only suspected this binomial. Furthermore, the process of immunization by the vaccines had not even started.